Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Clinical and Economic Benefits of Antimicrobial Stewardship Programs in Hemodialysis Facilities: A Decision Analytic Model.

D'Agata EMC, Tran D, Bautista J, Shemin D, Grima D.

Clin J Am Soc Nephrol. 2018 Sep 7;13(9):1389-1397. doi: 10.2215/CJN.12521117. Epub 2018 Aug 23.

PMID:
30139804
2.

The Assessment Of Value For Medical Devices: A Case Study On Injection Technique Education In Insulin Delivery.

Charter R, Hopley C, Su T, Grima D, Strauss K.

Value Health. 2015 Nov;18(7):A364. doi: 10.1016/j.jval.2015.09.717. Epub 2015 Oct 20. No abstract available.

3.

Xrn1/Pacman affects apoptosis and regulates expression of hid and reaper.

Waldron JA, Jones CI, Towler BP, Pashler AL, Grima DP, Hebbes S, Crossman SH, Zabolotskaya MV, Newbury SF.

Biol Open. 2015 Apr 2;4(5):649-60. doi: 10.1242/bio.201410199.

4.

A Microsoft-Excel-based tool for running and critically appraising network meta-analyses--an overview and application of NetMetaXL.

Brown S, Hutton B, Clifford T, Coyle D, Grima D, Wells G, Cameron C.

Syst Rev. 2014 Sep 29;3:110. doi: 10.1186/2046-4053-3-110.

5.

Cost-effectiveness of insulin glargine versus sitagliptin in insulin-naïve patients with type 2 diabetes mellitus.

Brown ST, Grima DG, Sauriol L.

Clin Ther. 2014 Nov 1;36(11):1576-87. doi: 10.1016/j.clinthera.2014.07.019. Epub 2014 Aug 20.

PMID:
25151573
6.

Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada.

Grima DT, Brown ST, Kamboj L, Bainey KR, Goeree R, Oh P, Ramanathan K, Goodman SG.

Clinicoecon Outcomes Res. 2014 Jan 24;6:49-62. doi: 10.2147/CEOR.S51052. eCollection 2014.

7.

The 5'-3' exoribonuclease Pacman (Xrn1) regulates expression of the heat shock protein Hsp67Bc and the microRNA miR-277-3p in Drosophila wing imaginal discs.

Jones CI, Grima DP, Waldron JA, Jones S, Parker HN, Newbury SF.

RNA Biol. 2013 Aug;10(8):1345-55. doi: 10.4161/rna.25354. Epub 2013 Jun 13.

8.

Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone.

Sung AD, Grima DT, Bernard LM, Brown S, Carrum G, Holmberg L, Horwitz ME, Liesveld JL, Kanda J, McClune B, Shaughnessy P, Tricot GJ, Chao NJ.

Bone Marrow Transplant. 2013 Nov;48(11):1444-9. doi: 10.1038/bmt.2013.80. Epub 2013 Jun 10.

9.

How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies.

Ferko NC, Borisova N, Airia P, Grima DT, Thompson MF.

Manag Care. 2012 Nov;21(11):44-52.

10.

Impact of sevelamer versus calcium-based binders on hospitalizations and missed in-center dialysis treatments among CKD patients on dialysis: a modeled analysis.

Grima DT, Dunn ES, Bernard LM, Mendelssohn DC.

Curr Med Res Opin. 2013 Feb;29(2):109-15. doi: 10.1185/03007995.2012.756808. Epub 2012 Dec 20.

PMID:
23216385
11.

Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs.

Grima DT, Bernard LM, Dunn ES, McFarlane PA, Mendelssohn DC.

Pharmacoeconomics. 2012 Nov 1;30(11):981-9. doi: 10.2165/11599390-000000000-00000.

PMID:
22946789
12.

A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.

Bernard L, Mendelssohn D, Dunn E, Hutchison C, Grima DT.

J Med Econ. 2013;16(1):1-9. doi: 10.3111/13696998.2012.718019. Epub 2012 Sep 10.

PMID:
22857538
13.
14.

Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.

Hutchison CA, Heyne N, Airia P, Schindler R, Zickler D, Cook M, Cockwell P, Grima D.

Nephrol Dial Transplant. 2012 Oct;27(10):3823-8. doi: 10.1093/ndt/gfr773. Epub 2012 Jan 23.

PMID:
22273664
15.

Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney.

Grima DT, Airia P, Attard C, Hutchison CA.

Curr Med Res Opin. 2011 Feb;27(2):383-91. doi: 10.1185/03007995.2010.543125. Epub 2010 Dec 23.

PMID:
21175375
16.
17.
18.

Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada.

Attard CL, Maroun JA, Alloul K, Grima DT, Bernard LM.

Curr Oncol. 2010 Feb;17(1):17-24.

19.

The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis.

Thompson M, Pasquale M, Grima D, Moehrke W, Kruse HP.

Value Health. 2010 Jan-Feb;13(1):46-54. doi: 10.1111/j.1524-4733.2009.00666.x. Epub 2009 Oct 26.

20.

Drosophila processing bodies in oogenesis.

Lin MD, Jiao X, Grima D, Newbury SF, Kiledjian M, Chou TB.

Dev Biol. 2008 Oct 15;322(2):276-88. doi: 10.1016/j.ydbio.2008.07.033. Epub 2008 Aug 5.

21.

The 5'-3' exoribonuclease Pacman is required for normal male fertility and is dynamically localized in cytoplasmic particles in Drosophila testis cells.

Zabolotskaya MV, Grima DP, Lin MD, Chou TB, Newbury SF.

Biochem J. 2008 Dec 15;416(3):327-35. doi: 10.1042/BJ20071720.

PMID:
18652574
22.

The 5'-3' exoribonuclease pacman is required for epithelial sheet sealing in Drosophila and genetically interacts with the phosphatase puckered.

Grima DP, Sullivan M, Zabolotskaya MV, Browne C, Seago J, Wan KC, Okada Y, Newbury SF.

Biol Cell. 2008 Dec;100(12):687-701. doi: 10.1042/BC20080049.

PMID:
18547166
23.

How many cardiovascular events can be prevented with optimal management of high-risk Canadians?

Grima DT, Leiter LA, Goodman SG, Attard CL, Chow CM, Langer A.

Can J Cardiol. 2008 May;24(5):363-8.

24.

Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.

Grima DT, Papaioannou A, Thompson MF, Pasquale MK, Adachi JD.

Osteoporos Int. 2008 May;19(5):687-97. Epub 2007 Nov 16.

25.

Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.

Grima DT, Thompson MF, Sauriol L.

Pharmacoeconomics. 2007;25(3):253-66.

PMID:
17335310
26.

Considerations in developing model-based economic evaluations of glaucoma treatment.

Althin R, Grima DT, Dhawan R, Bernard LM.

J Glaucoma. 2006 Dec;15(6):541-7.

PMID:
17106369
27.
28.

An economic evaluation of rizatriptan in the treatment of migraine.

Thompson M, Gawel M, Desjardins B, Ferko N, Grima D.

Pharmacoeconomics. 2005;23(8):837-50.

PMID:
16097844
29.

Intraocular pressure control and persistence on treatment in glaucoma and ocular hypertension.

Tingey D, Bernard LM, Grima DT, Miller B, Lam A.

Can J Ophthalmol. 2005 Apr;40(2):161-9.

PMID:
16049529
30.

Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.

Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E.

J Natl Cancer Inst. 2004 Apr 21;96(8):604-15.

PMID:
15100338
31.

Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States.

Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, Kulin NA, Weinstein MC.

Vox Sang. 2004 Jan;86(1):28-40.

PMID:
14984557
32.

Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France.

Bernard LM, Althin R, Dhawan R, Grima DT, Lam A, Aballéa S.

Eur J Ophthalmol. 2003 Jul;13 Suppl 4:S30-43.

PMID:
12948051
33.

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine.

Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E.

Int J Cancer. 2003 Oct 10;106(6):896-904.

34.

Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions.

Tosteson AN, Jönsson B, Grima DT, O'Brien BJ, Black DM, Adachi JD.

Osteoporos Int. 2001;12(10):849-57.

PMID:
11716188
35.

Cost and health related quality of life consequences of multiple sclerosis.

Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L.

Mult Scler. 2000 Apr;6(2):91-8.

PMID:
10773854
36.

Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis.

Rosner AJ, Grima DT, Torrance GW, Bradley C, Adachi JD, Sebaldt RJ, Willison DJ.

Pharmacoeconomics. 1998 Nov;14(5):559-73.

PMID:
10344918
37.

The total process cost of parenteral antibiotic therapy: beyond drug acquisition cost.

Hotchkies L, Grima DT, Hedayati S.

Clin Ther. 1996 Jul-Aug;18(4):716-25; discussion 702.

PMID:
8879899
38.

Orthovanadate inhibits interleukin-1 and phorbol ester induced collagenase production by chondrocytes.

Conquer JA, Grima DT, Cruz TF.

Ann N Y Acad Sci. 1994 Sep 6;732:447-9. No abstract available.

PMID:
7978835
39.

Lipocortin 2 (annexin 2) is a major substrate for constitutive tyrosine kinase activity in chondrocytes.

Grima DT, Kandel RA, Pepinsky B, Cruz TF.

Biochemistry. 1994 Mar 15;33(10):2921-6.

PMID:
7510517

Supplemental Content

Support Center